Varenicline

Overview

Varenicline (CP 526555) is an orally active partial agonist of α4β2 nicotinic acetylcholine receptor (α4β2 nAChR , IC 50 = 250 nM), which is the principal mediator of nicotine dependence. Varenicline is also a partial agonist of α6β2 nAChR and a full agonist of α7β2 nAChR . Varenicline blocks the direct agonist effects of nicotine on nAChR while stimulates nAChR in a more moderate way, being widely used as an aid of smoking cessation.

Application

Products | Products > Disease Areas > Coronavirus Infection | Products > Disease Areas > Neurodegenerative Disease | Products > Disease Areas > Pancreatic Cancer | Products > Disease Areas > Digestive System Cancer | Products > Disease Areas > Viral Infection | Products > Disease Areas > SARS-CoV-2 Infection | Products > Disease Areas > Alzheimer's Disease | Products > Disease Areas > Cancer | Products > Disease Areas > Infection | Products > Disease Areas > Neurological, Eye or Ear Disease | Products > Disease Areas > Digestive System Disease | Products > Disease Areas > Inflammation or Immune System Disease | Products > Signaling Pathways > Membrane Transporter/Ion Channel | Products > Signaling Pathways > Neuronal Signaling | Products > Research Areas > Neurological Disease | Products > Research Areas > Inflammation/Immunology | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > nAChR

Product Information

• Catalog No.: HY-10019
• CAS No.: 249296-44-4
• Molecular Formula: C13H13N3
• Molecular Weight: 211.27
• Purity: 99.92%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
• Solubility: ≥ 2.5 mg/mL (11.83 mM); Clear solution
• Availability: In-stock

Source

Original product source